TITLE

Schering renamed

PUB. DATE
February 2007
SOURCE
European Pharmaceutical Executive;Feb/Mar2007, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on Germany-based Schering AG's decision to change its name to Bayer Schering Pharma AG. The necessary entry in the commercial register took effect on December 29, 2006. The article also reports that the new logo has been mounted on Bayer Schering Pharma's headquarters in Berlin. It also discusses the company's plan to continue with its restructuring program.
ACCESSION #
24529552

 

Related Articles

  • New step for Bayer Schering.  // R&D Magazine;Jan2007, Vol. 49 Issue 1, p12 

    The article reports that Schering has been renamed to Bayer Schering Pharma AG following its acquisition by Bayer AG in July 2006. According to Werner Wenning, Bayer AG management board chairman, the firm is focusing on the next steps. Bayer Schering Pharma AG together with Bayer's...

  • TOP 20 PHARMA: #15 BAYER SCHERING.  // Contract Pharma;2009, Vol. 11 Issue 6, p84 

    The article profiles Bayer Schering Pharma AG, the rank 15 among the top 20 pharmaceutical companies based in Leverkusen, Germany. It notes that it was founded in 1971 and handles 108,600 employees. It mentions its plan to strengthen its research and development initiative in 2009 through its 4...

  • Schering and Bayer seal drug ownership agreement. Chynoweth, Emma // ICIS Chemical Business;4/2/2007, Vol. 2 Issue 60, p33 

    This article reports that Bayer Schering Pharma and Novartis have settled a dispute over U.S. production of the interferon-based multiple sclerosis treatment Betaseron, sold in the U.S. as Betaferon. The deal sees Bayer Schering Pharma acquiring most of Novartis' Emeryville, California, site,...

  • Bayer Schering job cuts. William, Dede; Gibson, Jane // ICIS Chemical Business Americas;3/5/2007, Vol. 271 Issue 9, p13 

    This article reports that Schering is set to cut 950 jobs at its headquarters in Berlin, Germany by 2009. Werner Wenning, Bayer chairman, said the move is due to the merger between the pharmaceutical activities of Schering and Bayer. Wenning, who is also chairman of Bayer Schering Pharma's...

  • European pharma consolidation generates quality spinoffs. Sheridan, Cormac // Nature Biotechnology;Dec2006, Vol. 24 Issue 12, p1458 

    The article focuses on the consolidation and acquisition of European pharmaceutical companies. The article discuses that Berlin based Schering company and two German companies are acquired by Bayer Healthcare, Germany, to establish Bayer-Schering Pharma. And the establishment will concentrate on...

  • COMPANY SPOTLIGHT -- Bayer Schering.  // PharmaWatch: CNS;Nov2010, Vol. 9 Issue 11, p19 

    The article features Bayer Schering Pharma AG. It relates that the pharmaceutical company is a research-based company which engaged in the manufacturing, developing, and marketing of pharmaceutical products. It says that the company focuses in four businesses including diagnostic imaging,...

  • BREAKING NEWS.  // Pharmaceutical Technology;Feb2007, Vol. 31 Issue 2, p20 

    The article presents a summary of news events from December 2006 to January 2007 in the pharmaceutical industry, which were published in the "Weekly Electronic Newsletter of Pharmaceutical Technology." In Berlin and Leverkusen, Germany, Bayer Schering Pharma was launched as a start up company...

  • EPIX Regains Vasovist Rights.  // BioWorld Today;9/5/2008, Vol. 19 Issue 173, p3 

    The article reports on the plan of EPIX Pharmaceuticals Inc. to regain full worldwide commercial rights for the imaging product Vasovist from Bayer Schering Pharma in 2008. EPIX hopes to have U.S. approval of the product by the end of the year. The firm had been awaiting word from Bayer on...

  • Lymphoma Update.  // PharmaWatch: Cancer;Jun2008, Vol. 7 Issue 6, p4 

    The article offers updates on the results of lymphoma trials by several pharmaceutical companies in Europe. Medarex Inc. announced data from its Phase I/II trial suggesting the dosage escalation of lymphoma antibodies to patients. Antisoma PLC revealed the effectiveness of its anti-nucleolin...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics